litlas
Log inCreate account

David A. Scheinberg

Active 1982–2025

110
Papers
20,888
Citations
79
h-index
110
i10-index

Citations

Citations per year for David A. Scheinberg1983: 7 citations1984: 8 citations1985: 4 citations1986: 5 citations1987: 2 citations1988: 3 citations1989: 5 citations1990: 6 citations1991: 10 citations1992: 42 citations1993: 30 citations1994: 18 citations1995: 22 citations1996: 14 citations1997: 20 citations1998: 28 citations1999: 86 citations2000: 85 citations2001: 130 citations2002: 126 citations2003: 114 citations2004: 147 citations2005: 135 citations2006: 87 citations2007: 134 citations2008: 151 citations2009: 115 citations2010: 153 citations2011: 167 citations2012: 162 citations2013: 202 citations2014: 138 citations2015: 150 citations2016: 173 citations2017: 170 citations2018: 260 citations2019: 489 citations2020: 621 citations2021: 614 citations2022: 445 citations2023: 436 citations2024: 572 citations2025: 315 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,453 citing papers, 35.5% of this breakdownChina: 926 citing papers, 13.4% of this breakdownGermany: 384 citing papers, 5.6% of this breakdownUnited Kingdom: 362 citing papers, 5.2% of this breakdownItaly: 252 citing papers, 3.6% of this breakdownFrance: 247 citing papers, 3.6% of this breakdownCanada: 230 citing papers, 3.3% of this breakdownJapan: 183 citing papers, 2.6% of this breakdownNetherlands: 157 citing papers, 2.3% of this breakdownAustralia: 156 citing papers, 2.3% of this breakdownIndia: 128 citing papers, 1.9% of this breakdownSpain: 114 citing papers, 1.6% of this breakdown
0%35.5%Other 19.1%

Institutions

Fields

  • Medicine57.2%
  • Biochemistry, Genetics and Molecular Biology24.5%
  • Immunology and Microbiology7.4%
  • Materials Science3.2%
  • Engineering1.8%
  • Health Professions1.1%
  • Other4.8%

Topics

  • CAR-T cell therapy research7.2%
  • Radiopharmaceutical Chemistry and Applications4.5%
  • Acute Myeloid Leukemia Research3.9%
  • Retinoids in leukemia and cellular processes3.8%
  • Immunotherapy and Immune Responses3.7%
  • Cancer Immunotherapy and Biomarkers3.2%
  • Other73.7%

Coauthors

All papers

Open in search
  1. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

    Authors: Yasin Şenbabaoğlu, Ron S. Gejman, Andrew Winer, Ming Liu, Eliezer M. Van Allen, Guillermo de Velasco, Diana Miao, Irina Ostrovnaya, Esther Drill, Augustin Luna, Nils Weinhold, William Lee, Brandon J. Manley, Danny N. Khalil, Samuel D. Kaffenberger, Ying‐Bei Chen, Ludmila Danilova, Martin H. Voss, Jonathan Coleman, Paul Russo, Victor E. Reuter, Timothy A. Chan, Emily H. Cheng, David A. Scheinberg, Ming O. Li, Toni K. Choueiri, James J. Hsieh, Chris Sander, A. Ari Hakimi - Genome biology 2016 cited by 1,042

  2. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Authors: Renier J. Brentjens, Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta Stefanski, Clare Taylor, Raymond Yeh, Shirley Bartido, Oriana Bórquez-Ojeda, Malgorzata Olszewska, Yvette Bernal, Hollie J. Pegram, Mark Przybylowski, Daniel Hollyman, Yelena Usachenko, Domenick Pirraglia, James Hosey, Elmer Santos, Elizabeth Halton, P. Maslak, David A. Scheinberg, Joseph G. Jurcic, Mark Heaney, Glenn Heller, Mark G. Frattini, Michel Sadelain - Blood 2011 cited by 1,284

  3. Acute myeloid leukaemia

    Authors: Asim Khwaja, Magnus Björkholm, Rosemary E. Gale, Ross L. Levine, Craig T. Jordan, Gerhard Ehninger, Clara D. Bloomfield, Eli Estey, Alan K. Burnett, Jan J. Cornelissen, David A. Scheinberg, Didier Bouscary, David C. Linch - Nature Reviews Disease Primers 2016 cited by 587

  4. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

    Authors: Smita S. Chandran, Jiaqi Ma, Martin G. Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi, Hannah Y. Wen, Britta Weigelt, Paul Zumbo, Si Ning Fu, Lauren B. Banks, Fei Yi, Enric Vercher, Iñaki Etxeberría, Watchain D. Bestman, Arnaud Da Cruz Paula, Ilinca Aricescu, Alexander Drilon, Doron Betel, David A. Scheinberg, Brian M. Baker, Christopher A. Klebanoff - Nature Medicine 2022 cited by 129

  5. Engineering CAR-T cells to activate small-molecule drugs in situ

    Authors: Thomas J. Gardner, J. Peter Lee, Christopher M. Bourne, Dinali Wijewarnasuriya, Nihar Kinarivala, Keifer G. Kurtz, Broderick C. Corless, Megan M. Dacek, Aaron Y. Chang, George Mo, Kha M. Nguyen, Renier J. Brentjens, Derek S. Tan, David A. Scheinberg - Nature Chemical Biology 2021 cited by 77

  6. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

    Authors: Megan M. Dacek, Keifer G. Kurtz, Patrick Wallisch, Stephanie Pierre, Shireen Khayat, Christopher M. Bourne, Thomas J. Gardner, Kristen Vogt, Nica Aquino, Anas Younes, David A. Scheinberg - Blood 2023 cited by 46

  7. Tumor Therapy with Targeted Atomic Nanogenerators

    Authors: Michael R. McDevitt, Dangshe Ma, Lawrence Lai, Jim Simón, Paul E. Borchardt, R. Keith Frank, Karen Wu, V Pellegrini, Michael Curcio, Matthias Miederer, Neil H. Bander, David A. Scheinberg - Science 2001 cited by 504

  8. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

    Authors: Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia‐Yuan Ying, Chi-Shuen Chu, Man Chun John, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta J. Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, José Baselga, Anas Younes, Cassian Yee, Ahmet Doǧan, David A. Scheinberg, Robert G. Roeder, Ari Melnick, Michael R. Green - Cancer Discovery 2020 cited by 159

  9. Paradoxical glomerular filtration of carbon nanotubes

    Authors: Alessandro Ruggiero, Carlos H. Villa, Evan D. Bander, Diego A. Rey, Magnus Bergkvist, Carl A. Batt, Katia Manova‐Todorova, William M. Deen, David A. Scheinberg, Michael R. McDevitt - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 418

  10. Rejection of immunogenic tumor clones is limited by clonal fraction

    Authors: Ron S. Gejman, Aaron Y. Chang, Heather F. Jones, Krysta M. DiKun, A. Ari Hakimi, Andrea Schietinger, David A. Scheinberg - eLife 2018 cited by 135

  11. Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells

    Authors: Elliott J. Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert, Qing Xiang, Aaron Y. Chang, Ralph Garippa, Taha Merghoub, Jedd D. Wolchok, Neal Rosen, Scott W. Lowe, David A. Scheinberg - Cancer Immunology Research 2016 cited by 176

  12. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

    Authors: P. Maslak, Tao Dao, Yvette Bernal, Suzanne Chanel, Rong Zhang, Mark G. Frattini, Todd Rosenblat, Joseph G. Jurcic, Renier J. Brentjens, Maria E. Arcila, Raajit K. Rampal, Jae H. Park, Dan Douer, Laura M. Katz, Nicholas J. Sarlis, Martin S. Tallman, David A. Scheinberg - Blood Advances 2018 cited by 159

  13. Alpha-Emitting Radionuclides: Current Status and Future Perspectives

    Authors: Matthias Miederer, Martina Benešová-Schäfer, Constantin Mamat, David Kästner, Marc Pretze, Enrico Michler, Claudia Brogsitter, Jörg Kotzerke, Klaus Kopka, David A. Scheinberg, Michael R. McDevitt - Pharmaceuticals 2024 cited by 55

  14. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

    Authors: Eric J. Feldman, Joseph Brandwein, Richard M. Stone, Matt Kalaycio, Joseph O. Moore, Julie O’Connor, Nancy Wedel, Gail J. Roboz, Carole B. Miller, Raj Chopra, Joseph C. Jurcic, Randy A. Brown, W. Christopher Ehmann, Philip Schulman, Stanley R. Frankel, Daniel De Angelo, David A. Scheinberg - Journal of Clinical Oncology 2005 cited by 249

  15. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

    Authors: Sarwish Rafiq, Terence J. Purdon, Anthony F. Daniyan, Mythili Koneru, Tao Dao, C Liu, David A. Scheinberg, Renier J. Brentjens - Leukemia 2016 cited by 150

  16. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1

    Authors: Sung Soo Mun, Jeremy Meyerberg, Leila Peraro, Tatyana Korontsvit, Thomas J. Gardner, Manish Malviya, Chrisann Kyi, Roisin E. O’Cearbhaill, Liu C, Tao Dao, David A. Scheinberg - Cancer Immunology Immunotherapy 2023 cited by 35

  17. Actinium-225 in Targeted Alpha-Particle Therapeutic Applications

    Authors: David A. Scheinberg, Michael R. McDevitt - Current Radiopharmaceuticals 2011 cited by 177

  18. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury

    Authors: Simone Alidori, Nima Akhavein, Daniel L.J. Thorek, Katja Behling, Yevgeniy Romin, Dawn Queen, Bradley J. Beattie, Katia Manova‐Todorova, Magnus Bergkvist, David A. Scheinberg, Michael R. McDevitt - Science Translational Medicine 2016 cited by 127

  19. Design and synthesis of 225Ac radioimmunopharmaceuticals

    Authors: Michael R. McDevitt, Dangshe Ma, Jim Simón, R. Keith Frank, David A. Scheinberg - Applied Radiation and Isotopes 2002 cited by 231

  20. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications

    Authors: Matthias Miederer, David A. Scheinberg, Michael R. McDevitt - Advanced Drug Delivery Reviews 2008 cited by 214

  21. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

    Authors: Todd L. Rosenblat, Michael R. McDevitt, Jorge A. Carrasquillo, Neeta Pandit-Taskar, Mark G. Frattini, Peter G. Maslak, Jae H. Park, Dan Douer, Dragan Cicic, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic - Clinical Cancer Research 2022 cited by 63

  22. Challenges and solutions for therapeuticTCR‐based agents

    Authors: Manish Malviya, Zita E. H. Aretz, Zaki Molvi, Jaeyop Lee, Stephanie Pierre, Patrick Wallisch, Tao Dao, David A. Scheinberg - Immunological Reviews 2023 cited by 31

  23. Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

    Authors: Todd Rosenblat, Michael R. McDevitt, Deborah Mulford, Neeta Pandit‐Taskar, Chaitanya Divgi, Katherine S. Panageas, Mark Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic - Clinical Cancer Research 2010 cited by 264

  24. Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

    Authors: Tao Dao, Su Yan, Nicholas Veomett, Dmitry Pankov, Liang Zhou, Tatyana Korontsvit, Andrew Scott, Joseph A. Whitten, P. Maslak, Emily Casey, Taochao Tan, Hong Liu, Victoria Zakhaleva, Michael Curcio, Ekaterina Doubrovina, Richard J. O’Reilly, Liu C, David A. Scheinberg - Science Translational Medicine 2013 cited by 180